EGM
FPRX

Engineers Gate Manager’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Engineers Gate Manager’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-18,400
Closed -$111K – 1705
2019
Q2 		$111K Buy
+18,400
New +$176K 0.01% 1048

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Engineers Gate Manager's FPRX Position: Q3 2019 in Review

Engineers Gate Manager sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2019, closing a stake of 18,400 shares — an estimated $111K sold.

Engineers Gate Manager first reported a position in FPRX in Q2 2019 and held it in 1 quarter. The position peaked at $111K in Q2 2019. 103 funds tracked by Wall St. Rank hold FPRX as of Q3 2019.

  • Engineers Gate Manager reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Engineers Gate Manager sold 18,400 Five Prime Therapeutics, Inc. shares in Q3 2019, an estimated $111K.
  • Engineers Gate Manager first reported a position in Five Prime Therapeutics, Inc. in Q2 2019 and held it in 1 quarter.
  • Engineers Gate Manager's Five Prime Therapeutics, Inc. position peaked at $111K in Q2 2019.
  • 103 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2019.

Based on Engineers Gate Manager's 13F filing for Q3 2019, filed 14 Nov 2019.